The abnormal accumulation of amyloid beta (Aβ) and tau protein in the brain measured by positron emission tomography (PET), as well as the levels of Aβ42 and phosphorylated tau181 (p-tau181) in cerebrospinal fluid (CSF), are the current core biomarkers of AD (Rabinovici et al., 2019; Hansson, 2021). The gene discussed is MAPT; the disease is Alzheimer disease.